Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan-O trial testing a titratable fixed-ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide (Q45402509)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan-O trial testing a titratable fixed-ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide |
scientific article |
Statements
1 reference
Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan-O trial testing a titratable fixed-ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide (English)
1 reference
1 reference
Julio Rosenstock
1 reference
George Grunberger
1 reference
Bruno Guerci
1 reference
F Javier Ampudia-Blasco
1 reference
Christine Yu
1 reference
William Stager
1 reference
Elisabeth Niemoeller
1 reference
Elisabeth Souhami
1 reference
1 reference
Identifiers
1 reference